Five antimicrobial drugs (ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin) and two human, intravenously applicable, IgG immunoglobulin preparations (Psomaglobin®, Polyglobin N®) were examined alone and in various combinations for therapeutic efficacy in myelosuppressed as well as normal NMRI mice following systemic infection with 4 selected strains of Pseudomonas aeruginosa. Both IgG preparations alone invariably failed to passively protect neutropenic and normal mice, even though the preparations contained demonstrable antibodies against purified exotoxin A of P. aeruginosa and against numerous polypeptide and lipopolysaccharide constituents of the 4 test strains of P. aeruginosa. Among the antimicrobial drugs employed alone, ciprofloxacin and imipenem were the most effective. Tobramycin alone occupied an intermediate position, whereas monotherapy with ceftazidime and piperacillin invariably failed. All antimicrobial drug combinations were efficacious in myelosuppressed as well as normal mice. Both IgG preparations failed to enhance the activities of ceftazidime and piperacillin in neutropenic mice; the activity of tobramycin was augmented against 1 of 2 P. aeruginosa strains, as well as that of ciprofloxacin. Both IgG preparations enhanced the activities of ceftazidime and tobramycin in normal NMRI mice, as well as that of piperacillin against 1 of 2 test strains. It was concluded that the two IgG preparations were more beneficial for normal rather than neutropenic mice, provided that the animals were treated with appropriate antimicrobial drugs as well.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.